FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington, D.C. 20049

OMB APP	ROVAL
OMB Number:	3235-02

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							. ,													
1. Name and Address of Reporting Person*  PARVEN ALVIN S						2. Issuer Name and Ticker or Trading Symbol ALEXION PHARMACEUTICALS INC ALXN									Check al		cable)	g Person(s) to I		
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year)										Officer below)	(give title	Other below	(specify )	
C/O ALEXION PHARMACEUTICALS INC 352 KNOTTER DRIVE					02/	02/21/2012														
(Street)					-   <sup>4. lf</sup>	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
CHESHI	RE CI	Γ (	06410														,	Reporting Per		
					-										Form filed by More than One Reporting Person					
(City)	(St	ate) (	Zip)																	
		Tabl	e I - No	on-Deriv	ative	Sec	uritie	s Ac	quired	d, Dis	sposed o	f, or	Ben	eficia	ally O	wned	ł			
1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day						Execution Date,					es Acquired (A) o Of (D) (Instr. 3, 4 a			and 5) Sec Ber Ow		ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						Code	v	Amount	(A) (D)	or	Price	Ti	Reported Transaction(s) (Instr. 3 and 4)			(111501.4)				
Common Stock, par value \$.0001 per share 02/21/20					2012				S		5,450	I	)	\$81.51(1)		1 <sup>(1)</sup> 7,311		D		
		Та	ıble II -								osed of, convertib				y Owr	ned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, if any		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration Da (Month/Day/Y		ite	7. Title and Amount of Securities Underlying Derivative Security (Ins and 4)		str. 3	8. Price Derivat Securit (Instr. §	tive d ty S 5) B C F R	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	or Nui of	ount mber ares						

## **Explanation of Responses:**

1. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$81.48 - \$81.56. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.

/s/ Alvin Parven

02/23/2012

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.